Synaptic’s SEA Technology

Synaptic is a noninvasive technology cleared to market by the FDA for pain relief. Simply speaking, Synaptic devices provide an electrical waveform that mimics indigenous central nervous system electrical waveforms. This stimulates the central nervous system.

At present the Synaptic Electronic Activation (SEA) technology is not being marketed for any medical use based on this underlying premise. For more than a decade, it has been a ‘diamond hidden in the rough’ that simply needed capital to raise it to the position in the health care marketplace that it is capable of occupying.

Company History

The Synaptic Corporation began doing business 16 years ago. At that time, management elected to sell the Synaptic medical device under a narrow regulatory provision that allowed it to be marketed as a “TENS” device. This enabled the Company to go into business on modest capitalization after FDA cleared but without investing in the clinical studies needed to make further claims. However, the Synaptic SEA technology was always significantly different then TENS devices—which cease relieving pain the moment they are switched off.

Over the years, the Company frequently received physician reports that, after treatment with the Synaptic device, patients with other medical conditions had positive results with pain as well as relief from seemingly unrelated disorders.

Dr. Leon M. Silverstone –who invented the technology– has continued to research clinical applications and completed two additional SEA patents that he assigned to the Company, giving the present technology patent coverage until 2018. These subsequently will be withdrawn and replaced by new, broader patents in a comprehensive world-wide IP protection strategy.

The Current Opportunity

In the view of its Directors, the Company presents an opportunity of proportions rarely encountered by small business investors with socially conscious motives. We believe the Synaptic technology is capable of returning to patients a quality of life that has been stolen from them by a wide range of painful issues for which there is no effective treatment today. In almost all cases, the chemical or invasive treatments now being utilized involve the use of only marginally effective drugs with significant side effects or dangerous surgeries with only moderate results. These approaches do not restore functioning and they are ineffective in relieving conditions that have robbed such patients of their quality of life.

A key first priority for the Company is to raise the funds necessary to undertake clinical testing to prove the effectiveness of the Synaptic technology in treating three neurological disorders with no effective treatment available in present medicine Synaptic’s SEA technology is already cleared by FDA’s for the following three categories: Acute Pain, Chronic Pain, and Acute Post-Surgical or Post-Traumatic Pain.)

A CD entitled “Synaptic Results with Patients” (available to potential investors but not to potential customers of Synaptic medical devices) shows graphically the results of the Synaptic technology in the treatment of patients with several of the potential target disorders. These cases do not constitute controlled studies of the type needed for a study for FDA review. But they do show that there is excellent reason to believe Synaptic’s SEA technology will prove effective when evaluated in controlled studies.

The Company’s intention is to engage experienced consultants for the design of clinical studies and skilled, independent medical researchers of high repute to conduct the clinical studies upon which the applications for marketing approvals will be founded. These will provide the basis for immense growth in shareholder value. Each such approval is expected to significantly affect share prices. In addition, we are identifying and licensing strategic partners that are abe to fast track development for target disorders and respond to anticipated demand.

Additional Information